Abigail Brooks, MA

The accelerated approval is based on data from the phase 3 ELATIVE trial demonstrating a reduction in alkaline phosphatase with elafibranor.

Strnad explains key findings from research presented at the EASL Congress regarding noninvasive testing and biomarkers in AATD-LD based on phase 2 fazirsiran clinical trials.

Congly explains key findings from his cross-sectional study of costs associated with HBV treatment in patients on Medicaid and the economic impact of generic versus originator use.

Phase 2 data presented at EASL showed 52 weeks of treatment with tirzepatide led to MASH resolution with no worsening of fibrosis in patients with MASH and F2/F3 fibrosis.

8 weeks of treatment with combination bemnifosbuvir and ruzasvir showed a 97% SVR rate at 12 weeks post-treatment in a phase 2 lead-in cohort.

Survodutide, a glucagon/GLP-1 receptor dual agonist, improved MASH with no worsening of fibrosis, reduced liver fat content, and improved fibrosis by ≥ 1 stage in a phase 2 trial.

Phase 2b data show combination bulevirtide and peginterferon alfa-2a therapy resulted in greater percentages of undetectable HDV RNA versus bulevirtide alone.

Qazi discusses implications from a recent study exploring the impact of post-IPAA cuffitis on long-term pouch outcomes and the risk of developing strictures and fistulas.

Qazi reviews findings from a recent study suggesting glucagon does not have a significant impact on esophageal foreign body impaction resolution.

Qazi discusses the impact of bariatric surgery on outcomes in patients with decompensated cirrhosis, highlighting its benefit in this patient population.

In our nephrology month in review for May 2024, we spotlight the biggest news from the NKF and ERA meetings, including the latest updates in IgA nephropathy, C3 glomerulopathy, chronic kidney disease, and more!

Late-breaking phase 3 data presented at EASL show elafibranor’s impact on managing PBC progression and improving itch-related quality of life in patients with pruritus.

The May 2024 gastroenterology month in review spotlights top research from Digestive Disease Week 2024 and the FDA approval of ColoSense.

Alkhouri explains the unmet need in MASH leading up to resmetirom’s historic FDA approval and the impact its availability has had for both patients and clinicians.

Results suggest certain peroxiredoxins may be viable prognostic markers in glomerulopathies, including IgA nephropathy and membranous nephropathy.

Sands reviews key findings from the phase 3 VIVID-1 study of mirikizumab in Crohn’s disease presented at DDW.

Using available literature, the review assesses our current understanding of AATD, emerging biomarkers, and the future of drug development.

The case-control study found the prevalence of MASLD was greater among patients with plaque psoriasis, further suggesting a potential synergistic role between the two.

Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.

In honor of World Digestive Health Day, this feature examines the growth of intestinal ultrasound in IBD care in the US and how it aligns with STRIDE-II guidance.

Patients with AATD had increased cardiovascular risk compared to non-AATD COPD and healthy controls, with results suggesting physiological tests may assess risk more accurately.

Bonder explains key therapeutic targets in primary biliary cholangitis and why combination obeticholic acid and bezafibrate may be a promising option.

Lembo describes the potential of a multi-species synbiotic for the treatment of IBS based on findings from an exploratory study he presented at DDW.

Lacy reviews key considerations for the diagnostic evaluation and treatment of abdominal bloating and distension based on his session at DDW.

Aby describes findings from a pair of studies presented at DDW exploring the prevalence and impact of financial burden in liver transplant candidates.

Singh explains a potential new approach to the low FODMAP diet based on findings from research he presented at DDW suggesting a simplified step-up method.

Krugliak Cleveland explains findings from research she presented at DDW comparing intestinal ultrasound and conventional approaches to disease monitoring in IBD.

Rezaie reviews findings from a prospective clinical trial of a novel palatable elemental diet, highlighting its 100% compliance rate and strong efficacy.

Panaccione explains findings from GALAXI 2 and GALAXI 3 demonstrating guselkumab’s superiority to ustekinumab in Crohn’s disease, presented at DDW.